Related Experiment Video
Updated: Mar 14, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.2K
Pharmacogenomic approaches to lipid-regulating trials
Marie-Jeanne Bertrand1, Marie-Pierre Dubé, Jean-Claude Tardif
1aMontreal Heart Institute bFaculty of Medicine, Université de Montréal cBeaulieu-Saucier Pharmacogenomics Centre, Université de Montréal, Montreal, Québec, Canada.
Current Opinion in Lipidology
|September 28, 2016
Summary
Pharmacogenomics can improve cardiovascular drug development by identifying patient subgroups who benefit most from therapies like statins. This approach reduces trial failures and enhances treatment efficacy, minimizing residual cardiovascular risk.
Area of Science:
- Cardiovascular Medicine
- Pharmacogenomics
- Genetics
Background:
- Cardiovascular drug development faces challenges including high costs, long trial durations, and modest results, hindering progress.
- Statins have reduced cardiovascular events, yet significant residual risk persists due to difficulties in demonstrating additional benefits and inter-individual drug response variability.
Purpose of the Study:
- To explore the potential of pharmacogenomics in improving cardiovascular drug development and repurposing medications.
- To address the limitations of traditional clinical trials in unselected populations.
Main Methods:
- Review of genomic studies identifying variants associated with drug responses, particularly statins.
- Analysis of recent findings linking ADCY9 gene variants to dalcetrapib response.
Main Results:
- Gene variants associated with statin effects on plasma lipids have been identified.
- ADCY9 gene variants demonstrated significant associations with clinical outcomes, atherosclerosis imaging, cholesterol efflux, and inflammation in response to dalcetrapib.
Conclusions:
- Pharmacogenomics offers a promising strategy to decrease failure rates in future lipid trials.
- Identifying genetically determined populations can enhance drug development and personalize treatment for greater patient benefit and reduced risk.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
93
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
93
01:27Pharmacogenetics of Drug Metabolism: Overview
88
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
88
01:29Pharmacogenetics and Pharmacogenomics: Overview
117
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
117
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
90
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
90
01:27Principles of Pharmacogenetics: Types of Genetic Variants
72
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
72